Cardiovascular Safety of Long-term Topical Application of a New Non-steroidal Anti-inflammatory Drug, S-flurbiprofen, in Patients with Osteoarthritis

Ikuko Yataba, Yukikazu Kamada, Isao Matsushita, Hideo Matsumoto, Yuichi Hoshino, Akira Sato

Research output: Contribution to journalArticle

Abstract

Background S-flurbiprofen plaster (SFPP) is a newly developed tape-type patch of nonsteroidal anti-inflammatory drugs (NSAIDs), containing S-flurbiprofen (SFP) as an active ingredient. SFPP exhibits a significant clinical efficacy owing to the dramatically improved penetration of the active ingredient into deep tissues via good percutaneous absorption. The cardiovascular (CV) effects can be one of the class effects and they are worthy of attention. Therefore, we exploratory investigated the CV effect of SFPP, which results in comparable systemic exposure to that of oral flurbiprofen after long-term application in elderly patients with osteoarthritis. Methods A total of 201 patients with osteoarthritis (mean age, 66.3 years; 151 females) were treated with SFPP at 40 or 80 mg for 52 weeks. CV events observed after the application of SFPP were investigated. Results CV adverse events were observed in 4.5% (9/201 patients); however, none of them was classified as severe. Eight of the nine patients, who showed CV events, had CV diseases and/or hypertension at baseline. Any causal relationship between SFPP and CV events was denied by investigators on the basis of the patients' clinical courses. There was no relationship between CV events and plasma concentration of SFP in these patients. Conclusions Although CV events were observed in 4.5% of the patients after the application of SFPP, no apparent causal relationship between SFPP and CV events was observed on the basis of the clinical course and plasma SFP concentration.

Original languageEnglish
Pages (from-to)395-404
Number of pages10
JournalJapanese Pharmacology and Therapeutics
Volume47
Issue number3
Publication statusPublished - 2019 Jan 1

Fingerprint

Flurbiprofen
Osteoarthritis
Anti-Inflammatory Agents
Safety
Pharmaceutical Preparations
Skin Absorption

Keywords

  • Cardiovascular Disease
  • Clinical Trial
  • Long-Term
  • Non-Steroidal Anti-Inflammatory Drug
  • S-Flurbiprofen

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Cardiovascular Safety of Long-term Topical Application of a New Non-steroidal Anti-inflammatory Drug, S-flurbiprofen, in Patients with Osteoarthritis. / Yataba, Ikuko; Kamada, Yukikazu; Matsushita, Isao; Matsumoto, Hideo; Hoshino, Yuichi; Sato, Akira.

In: Japanese Pharmacology and Therapeutics, Vol. 47, No. 3, 01.01.2019, p. 395-404.

Research output: Contribution to journalArticle

Yataba, Ikuko ; Kamada, Yukikazu ; Matsushita, Isao ; Matsumoto, Hideo ; Hoshino, Yuichi ; Sato, Akira. / Cardiovascular Safety of Long-term Topical Application of a New Non-steroidal Anti-inflammatory Drug, S-flurbiprofen, in Patients with Osteoarthritis. In: Japanese Pharmacology and Therapeutics. 2019 ; Vol. 47, No. 3. pp. 395-404.
@article{16c96aea253f4d4ca8ad2a1b002b5070,
title = "Cardiovascular Safety of Long-term Topical Application of a New Non-steroidal Anti-inflammatory Drug, S-flurbiprofen, in Patients with Osteoarthritis",
abstract = "Background S-flurbiprofen plaster (SFPP) is a newly developed tape-type patch of nonsteroidal anti-inflammatory drugs (NSAIDs), containing S-flurbiprofen (SFP) as an active ingredient. SFPP exhibits a significant clinical efficacy owing to the dramatically improved penetration of the active ingredient into deep tissues via good percutaneous absorption. The cardiovascular (CV) effects can be one of the class effects and they are worthy of attention. Therefore, we exploratory investigated the CV effect of SFPP, which results in comparable systemic exposure to that of oral flurbiprofen after long-term application in elderly patients with osteoarthritis. Methods A total of 201 patients with osteoarthritis (mean age, 66.3 years; 151 females) were treated with SFPP at 40 or 80 mg for 52 weeks. CV events observed after the application of SFPP were investigated. Results CV adverse events were observed in 4.5{\%} (9/201 patients); however, none of them was classified as severe. Eight of the nine patients, who showed CV events, had CV diseases and/or hypertension at baseline. Any causal relationship between SFPP and CV events was denied by investigators on the basis of the patients' clinical courses. There was no relationship between CV events and plasma concentration of SFP in these patients. Conclusions Although CV events were observed in 4.5{\%} of the patients after the application of SFPP, no apparent causal relationship between SFPP and CV events was observed on the basis of the clinical course and plasma SFP concentration.",
keywords = "Cardiovascular Disease, Clinical Trial, Long-Term, Non-Steroidal Anti-Inflammatory Drug, S-Flurbiprofen",
author = "Ikuko Yataba and Yukikazu Kamada and Isao Matsushita and Hideo Matsumoto and Yuichi Hoshino and Akira Sato",
year = "2019",
month = "1",
day = "1",
language = "English",
volume = "47",
pages = "395--404",
journal = "Japanese Pharmacology and Therapeutics",
issn = "0386-3603",
publisher = "Life Science Publishing Co. Ltd",
number = "3",

}

TY - JOUR

T1 - Cardiovascular Safety of Long-term Topical Application of a New Non-steroidal Anti-inflammatory Drug, S-flurbiprofen, in Patients with Osteoarthritis

AU - Yataba, Ikuko

AU - Kamada, Yukikazu

AU - Matsushita, Isao

AU - Matsumoto, Hideo

AU - Hoshino, Yuichi

AU - Sato, Akira

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background S-flurbiprofen plaster (SFPP) is a newly developed tape-type patch of nonsteroidal anti-inflammatory drugs (NSAIDs), containing S-flurbiprofen (SFP) as an active ingredient. SFPP exhibits a significant clinical efficacy owing to the dramatically improved penetration of the active ingredient into deep tissues via good percutaneous absorption. The cardiovascular (CV) effects can be one of the class effects and they are worthy of attention. Therefore, we exploratory investigated the CV effect of SFPP, which results in comparable systemic exposure to that of oral flurbiprofen after long-term application in elderly patients with osteoarthritis. Methods A total of 201 patients with osteoarthritis (mean age, 66.3 years; 151 females) were treated with SFPP at 40 or 80 mg for 52 weeks. CV events observed after the application of SFPP were investigated. Results CV adverse events were observed in 4.5% (9/201 patients); however, none of them was classified as severe. Eight of the nine patients, who showed CV events, had CV diseases and/or hypertension at baseline. Any causal relationship between SFPP and CV events was denied by investigators on the basis of the patients' clinical courses. There was no relationship between CV events and plasma concentration of SFP in these patients. Conclusions Although CV events were observed in 4.5% of the patients after the application of SFPP, no apparent causal relationship between SFPP and CV events was observed on the basis of the clinical course and plasma SFP concentration.

AB - Background S-flurbiprofen plaster (SFPP) is a newly developed tape-type patch of nonsteroidal anti-inflammatory drugs (NSAIDs), containing S-flurbiprofen (SFP) as an active ingredient. SFPP exhibits a significant clinical efficacy owing to the dramatically improved penetration of the active ingredient into deep tissues via good percutaneous absorption. The cardiovascular (CV) effects can be one of the class effects and they are worthy of attention. Therefore, we exploratory investigated the CV effect of SFPP, which results in comparable systemic exposure to that of oral flurbiprofen after long-term application in elderly patients with osteoarthritis. Methods A total of 201 patients with osteoarthritis (mean age, 66.3 years; 151 females) were treated with SFPP at 40 or 80 mg for 52 weeks. CV events observed after the application of SFPP were investigated. Results CV adverse events were observed in 4.5% (9/201 patients); however, none of them was classified as severe. Eight of the nine patients, who showed CV events, had CV diseases and/or hypertension at baseline. Any causal relationship between SFPP and CV events was denied by investigators on the basis of the patients' clinical courses. There was no relationship between CV events and plasma concentration of SFP in these patients. Conclusions Although CV events were observed in 4.5% of the patients after the application of SFPP, no apparent causal relationship between SFPP and CV events was observed on the basis of the clinical course and plasma SFP concentration.

KW - Cardiovascular Disease

KW - Clinical Trial

KW - Long-Term

KW - Non-Steroidal Anti-Inflammatory Drug

KW - S-Flurbiprofen

UR - http://www.scopus.com/inward/record.url?scp=85064462386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064462386&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 395

EP - 404

JO - Japanese Pharmacology and Therapeutics

JF - Japanese Pharmacology and Therapeutics

SN - 0386-3603

IS - 3

ER -